BI-1808
Based on 1 Customer Validation
BI-1808 is a fully human IgG1 monoclonal antibody targeting human tumor necrosis factor receptor 2 (TNFR2) (KD = 646 pM). BI-1808 inhibits Treg survival by blocking the interaction between TNFR2 and its ligand TNF-α, and via its IgG1 Fc segment binds FcγR to target and deplete intratumoral Tregs (ADCC/ADCP) and induce pro-inflammatory reprogramming of myeloid cells, ultimately activating CD8+ effector T cell-mediated tumor rejection. BI-1808 can produce synergistic antitumor effects with Pembrolizumab (HY-P9902). BI-1808 can be used for research in tumor immunity.
For research use only. We do not sell to patients.
- Purity : 97.75%
- Molecular Weight:144.206 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
TNFR2 0.646 nM (Kd) |
TNF-α 0.37 nM (IC50) |
In Vitro
BI-1808 (7 days) exhibits agonistic effects in inducing Treg cell and CD8+ effector T cell expansion in human Naive CD3+ T cells under crosslinking conditions, with EC50 values of 5.44 nM and 9.12 nM, respectively[2].
BI-1808 (4 h) exerts an agonistic effect on NF-κB signaling induction in TNFR2-NF-κB co-expressing HEK-293 cells (co-cultured with FcγR + Jurkat cells)[2].
BI-1808 (50 μM; pretreated overnight followed by 5-day co-culture) reverses Treg-mediated immunosuppression in in vitro-differentiated Tregs (mixed with Naive CD3+ T cells)[2].
BI-1808 (10 μg/mL; 24 h) has a remodeling effect in human primary monocytes, increasing CD16, HLA-DR, and CD86 expression, promoting TNFα secretion, and reducing IL-10 secretion[3].
BI-1808 binds CHO-K1/hTNFR2 cells with an EC50 of 0.22 nM and binds primary Tregs with an EC50 of 0.053 nM[2].
BI-1808 (1 h) blocks the binding of human TNF-α to human TNFR2 in CHO-K1/hTNFR2 cells with an IC50 of 0.37 nM[2].
BI-1808 (1 h) exhibits targeted binding in in vitro activated human primary CD4+ T cells, with an EC50 of 2.6 nM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human primary T cells
-
Concentration:10 μg/mL
-
Incubation Time:72 h
-
Result:Blocked CD3/CD28-mediated T-cell proliferation.
-
Cell Line:human primary monocytes
-
Concentration:10 μg/mL
-
Incubation Time:24 h
-
Result:Promoted the secretion of the pro-inflammatory cytokine TNFα, and significantly reduced the secretion of the anti-inflammatory cytokine IL-10.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TNFR2-humanized mice were subcutaneously injected with 1 x 106 MC38 murine colon
adenocarcinoma cells
[2] -
Dosage:10 mg/kg
-
Administration:i.p.; twice weekly; for 3 weeks
-
Result:Inhibited tumor growth and reduced tumor volume.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of HepG2 cells with BI-1808 (HY-P991192, red) . Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa(HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Molecular Weight 144.206 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)